Medlab Clinical Ltd (ASX: MDC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Medlab Clinical Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$15.07 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
2.28 million
Earnings per share
-547.781
Dividend per share
N/A
Year To Date Return
N/A
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Medlab Clinical Ltd (ASX: MDC)
Latest News
⏸️ Investing
Here are 2017's best performing ASX pot stocks
⏸️ Investing
Here's Medlab Clinical Ltd's 'world first' plan to test cannabis on Sydney patients
❮2
MDC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Medlab Clinical Ltd
Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Matthew John Hudson | Non-Executive Director | Mar 2023 |
Mr Hudson has experience raising capital for projects based in Africa, Latin America, and Asia. He is a former Credit Suisse and Arthur Andersen advisor, who is now the Co Founder and Managing Director of Hudson Koch Energy. He is also the Founder and Managing Director of United Minerals which operated the historic Potosi Mine in Chihuahua, Mexico.
|
| Mr Sean Michael Hall | Chief Executive Officer | Apr 2014 |
Dr Hall has over 20 years experience in the Australian Healthcare and food industries and early phase drug discovery in Australia and Asia. Sean is best known for building Australia's leading practitioner brand, BioCeuticals. Dr Hall is an active member of Medicines Australia, American Federation for Medical Research, American Academy of Anti-Ageing Medicine, Ausbiotech, a member of the Scientific Advisory Board for BITs Life Science China and a Board Member of the International Probiotics Association.
|
| Mr Tim Walker | Non-Executive Director | Mar 2024 |
Mr Walker has experience in originating, managing, and leading a variety resource transaction. Specifically, in M&A transactions across the Canadian and Australian markets, IPOs, and both equity and debt financing solutions. Tims past directorships with exploration companies have provided him a experience across various commodity groups, including lithium exploration, rare earth and niobium hosted carbonatite deposits, whilst also having experience transacting on iron ore and base metal projects.
|
| Mr Edmond Tan | Non-Executive Director | Mar 2024 |
Mr Tan has 10 years experience in various roles which include Private Wealth Management, Family Office, and Structured Finance. In addition, he was involved in the establishment of a mid-market private equity joint venture fund with a specific focus on foreign investment into Australia. Currently, Edmond is a Director of Regenerate Pty Ltd a rare earth magnet recycling technology based in Houston, Texas. He is also the Australian Representative for Obsidian Global Partners LLC, a structured financier for ASX listed companies.
|
| Mr Kerem Kaya | Chief Financial OfficerCompany Secretary | May 2021 |
-
|
| Kerem Kaya | Chief Financial OfficerCompany Secretary |
-
|
|
| Ian Curtinsmith | Chief Information Officer |
-
|
|
| Luis Vitetta | Director of Medical Research |
-
|
|
| David Rutolo | Director of Science |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Sean Michael Hall | 386,838 | 16.94% |
| Farjoy Pty Ltd | 205,663 | 9.01% |
| HSBC Custody Nominees (Australia) Limited | 106,111 | 4.65% |
| UBS Nominees Pty Ltd | 85,316 | 3.74% |
| Fit Investments Pty Ltd <Hallab Investment A/C> | 75,563 | 3.31% |
| BNP Paribas Nominees Pty Ltd | 73,787 | 3.23% |
| Realm Group Pty Ltd | 70,000 | 3.07% |
| Richard Albarran <Albarran Family No 2 A/C> | 37,038 | 1.62% |
| Rolay Pty Ltd | 37,038 | 1.62% |
| United Trolley Collections P/L | 32,970 | 1.44% |
| Mr Michael Jack Hall + Mrs Elizabeth Ann Jones <Hall Jones Super Fund A/C> | 29,820 | 1.31% |
| Citicorp Nominees Pty Limited | 21,193 | 0.93% |
| Villamagna Inc | 20,000 | 0.88% |
| Netwealth Investments Limited | 18,839 | 0.83% |
| Acron Holdings Pty Limited <Acron Super Fund A/C> | 16,181 | 0.71% |
| Assumo (Nominees) Pty Ltd <Assumo Super Fund A/C> | 13,334 | 0.58% |
| D J Fairfull Pty Ltd <Fairfull Super Fund A/C> | 12,651 | 0.55% |
| Miss Xiaodan Fu | 11,902 | 0.52% |
| Deni Freighters Super Fund Pty Ltd <Deniliquin Freighters Super Fund A/C> | 10,001 | 0.44% |
| Daniel P Moses (Nominees) Pty Ltd <Daniel Moses Family A/C> | 10,000 | 0.44% |
